| Literature DB >> 26439630 |
Elsa Jacouton1, Núria Mach2, Julie Cadiou2, Nicolas Lapaque2, Karine Clément3, Joël Doré4, Johan E T van Hylckama Vlieg5, Tamara Smokvina5, Hervé M Blottière4.
Abstract
BACKGROUND AND OBJECTIVES: Identification of new targets for metabolic diseases treatment or prevention is required. In this context, FIAF/ANGPTL4 appears as a crucial regulator of energy homeostasis. Lactobacilli are often considered to display beneficial effect for their hosts, acting on different regulatory pathways. The aim of the present work was to study the effect of several lactobacilli strains on Fiaf gene expression in human intestinal epithelial cells (IECs) and on mice tissues to decipher the underlying mechanisms. SUBJECTS AND METHODS: Nineteen lactobacilli strains have been tested on HT-29 human intestinal epithelial cells for their ability to regulate Fiaf gene expression by RT-qPCR. In order to determine regulated pathways, we analysed the whole genome transcriptome of IECs. We then validated in vivo bacterial effects using C57BL/6 mono-colonized mice fed with normal chow.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26439630 PMCID: PMC4595210 DOI: 10.1371/journal.pone.0138880
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Effect of L. rhamnosus and L. paracasei on Fiaf expression in IECs. Cells were stimulated 6h with 20% of final volume of bacterial cultures.
Bars represent mean of Fiaf relative expression (percentage of rosiglitazone) from two to seven independent experiments performed in triplicates. Clear bars correspond to L. paracasei strains and dark bars correspond to L. rhamnosus strains. Data are normalized using β-Actin as control gene. Stars represent p<0.001 (***) in comparison with negative control (DMEM).
Fig 2L. rhamnosus CNCMI–4317 may induce Fiaf in a PPAR-α independent (a) but PPAR-γ dependent (b) manner. The antagonists (GW7647 and GW9662) were respectively added at 1 and 10μM 1h before challenging with agonists (GW6471 and rosiglitazone) during 6h.
Bars represent means of Fiaf relative expression (percentage of rosiglitazone and GW7647 respectively) from three independent experiments performed in triplicates. Data are normalized using β-Actin as control gene and by GW7647 (a) or rosiglitazone (b). Stars represent p<0.05 (*), p< 0.01 (**) and p<0.001 (***) in comparison with negative control (DMEM). ns represent a non significant difference between L. rhamnosus CNCMI- 4317 versus L. rhamnosus CNCMI—4317 supplemented with GW9662.
Fig 3Bacterial effectors characterization. (a) Conditioned media, (b) Heat inactivated bacteria, (c) Transwell. Cells were incubated 6h with 10% of final volume of bacterial fractions (CM, HI) and 20% of bacteria for transwell structure. Transwell prevented contact between cells and bacteria.
Bars represent means of Fiaf relative expression (percentage of rosiglitazone) from three independent experiments performed in triplicates. Data are normalized using β-Actin as control gene. Stars represent p<0.05 (*), p<0.01 (**) and p<0.001 (***) in comparison with negative control (DMEM). ns represents a no significant difference in comparison with negative control.
Fig 4IECs transcriptome analysis in presence of L. rhamnosus CNCMI–4317 and rosiglitazone; (a) Venn diagram, (b) IPA networks detected when comparing L. rhamnosus CNCMI–4317 to negative control or rosiglitazone treatment (c) to negative control in IECs, (d) validation of microarray modulated genes by RT-qPCR.
(b) FC are expressed in comparison with negative control (DMEM treatment), ns means that gene was not statistically significantly regulated by the treatment. Up-regulated genes are represented in grey shade except DKK1, which is down-regulated. (c) The networks included genes involved in neurological disease, cell cycle and cell development or Energy production, Lipid metabolism and small molecule biochemistry presented a score of 41 and 28 respectively (few genes are deleted to network for better view). The network displayed graphically as nodes (gene/gene products) and edges (the biological relationship between nodes). The node grey intensity indicates the expression of genes: black and bold: up-regulated, grey: down-regulated in intestinal tissues. The shapes of nodes indicate the functional class of the gene product. The log fold change values are indicated under each node. PPAR signalling canonical pathway was added. CP mean canonical pathway. (d) RT-qPCR data are normalized using geometrical mean of β-Actin and Gapdh as control genes.
List of regulated genes revealed by transcriptomic analysis after rosiglitazone or L. rhamnosus treatment of HT–29 cells.
| Description | Adj p-value | FC rosiglitazone | FC CNCMI–4317 | |
|---|---|---|---|---|
|
| ||||
|
| Angiopoietin like 4 | 1,8.10−4/8,9.10−4 | 1,67 | 1,63 |
|
| Serta domain containing 2 | 2,6.10−2 | ns | 1,32 |
|
| VGF nerve growth factor inducible | 3,8.10−2 | ns | 1,14 |
|
| Acyl-COA synthetase long-chain family member 5 | 2,9.10−2 | 1,19 | ns |
|
| Perilipin 2 | 3,2.10−4 | 1,51 | ns |
|
| Thrombospondin 1 | 3.2.10−4 | 1,59 | ns |
|
| Carnitine palmitoyltransferase 1A (liver) | 4,8.10−2 | 1,12 | ns |
|
| ELOVL fatty acid elongase 6 | 3,8.10−2 | 1,31 | ns |
|
| Peroximal biogenesis factor 13 | 1,8.10−2 | 1,11 | ns |
|
| ||||
|
| Pyruvate dehydrogenase kinase, isoenzyme 4 | 4.10−2 | 1,24 | ns |
|
| Sequestosome 1 | 3,3.10−2 | 1,19 | ns |
|
| Keratin 6A | 1,7.10−2 | 1,14 | ns |
|
| Hyaluronan synthase 3 | 1,8.10−2 | 1,24 | ns |
|
| Solute carrier family 2 (facilitated glucose transporter), member 3 | 1,8.10−2 | ns | 1,43 |
|
| Starch binding domain 1 | 3,8.10−2 | ns | 1,17 |
|
| ||||
|
| Zinc finger CCCH-type containing 8 | 3,8.10−2 | ns | -1,18 |
|
| Axis inhibition protein 2 | 3,6.10−2 | ns | -1,24 |
|
| Potassium channel tetramerization domain containing 11 | 2,1.10−2 | ns | 1,33 |
|
| Sins 3A-associated protein, 30kDa | 4,4.10−3 | ns | 1,26 |
|
| Nuclear receptor coactivator 5 | 2,1.10−2 | ns | -1,29 |
|
| Mitochondrial transcription termination factor | 3,8.10−2 | ns | -1,14 |
|
| Early growth response 3 | 5,7.10−3 | ns | 1,16 |
|
| HES family bHLH transcription factor 1 | 3,8.10−2 | ns | 1,17 |
|
| Early growth response 2 | 1,17.10−2 | ns | 1,13 |
|
| Basic-helix-loop-helix family, member 40 | 5,1.10−4 | ns | 1,96 |
|
| Early growth response 1 | 2,1.10−2 | ns | 1,51 |
|
| Eukaryotic translation initiation factor 5 | 3,4.10−2 | ns | -1,13 |
|
| ||||
|
| Adrenomedullin | 2,5.10−2 | ns | 1,66 |
|
| RNA binding motif protein 5 | 2,3.10−2 | ns | -1,27 |
|
| Immediate early response 3 | 4,9.10−3 | ns | 1,44 |
|
| Modulator apoptosis 1 | 1,6.10−2 | ns | 1,18 |
|
| Pim–1 oncogene | 5,1.10−4 | ns | 1,47 |
|
| P53 and DNA damage regulated 1 | 2,9.10−2 | ns | -1,23 |
|
| Ubiquitin-like with PDH and ring finger domain 1 | 3,3.10−2 | ns | -1,15 |
|
| Diskkopf WNT signaling pathway inhibitor 1 | 4,8.10−2 | -1,16 | ns |
|
| DNA binding 2, dominant negative helix-loop-helix protein | 1,4.10−2 | -1,15 | ns |
|
| Interleukin–1 receptor associated kinase 2 | 4.10−2 | 1,26 | ns |
|
| ||||
|
| Jun proto-oncogene | 1,7.10−2 | ns | 1,33 |
|
| Anoctamin 6 | 2,6.10−2 | ns | 1,17 |
|
| Kruppel-like factor 9 | 3,8.10−2 | ns | 1,2 |
|
| ||||
|
| Cyclin F | 2,1.10−2 | ns | -1,25 |
|
| Arrestin domain containing 3 | 2,8.10−4 | ns | 1,56 |
|
| Tubulin, beta 4B class IVb | 3,3.10−2 | ns | -1,3 |
|
| Calcium/calmodullin-dependent protein kinase II inhibitor | 2,2.10−2 | ns | 1,21 |
|
| Growth differentiation factor 15 | 4,4.10−3 | ns | 1,51 |
|
| CDC-like kinase 1 | 1,9.10−2 | ns | 1,2 |
|
| Dual specific phosphatase 5 | 2,8.10−2 | ns | 1,39 |
|
| ZFP36 Ring finger protein | 2,1.10−2 | ns | 1,58 |
|
| DNA-damage-inducible transcript 4 | 3,0.10−3 | ns | 2,7 |
|
| Platelet-derived growth factor alpha polypeptide | 3,8.10−2 | ns | 1,14 |
|
| ERO-like ( | 1,1.10−2 | ns | 1,2 |
|
| ||||
|
| myelin protein zero-like 2 | 4,1.10−2 | ns | 1,1 |
|
| Tripartite motif containing 8 | 3,6.10−2 | ns | 1,15 |
|
| Forkhead box D1 | 4,5.10−2 | ns | 1,17 |
|
| Interferon-related developmental regulator 1 | 3,4.10−2 | ns | -1,21 |
|
| Cysteine-serine-rich nuclear protein 1 | 1,1.10−2 | ns | 1,32 |
|
| GINS complex subunit 3 | 3,3.10−2 | ns | -1,21 |
|
| Intermediate filament family orphan 1 | 4,9.10−2 | ns | 1,17 |
|
| Lemur tyrosine kinase 3 | 3,1.10−2 | ns | 1,32 |
|
| Headcase homolog (Drosphila) | 2,1.10−2 | ns | 1,34 |
|
| Arginine/serine coiled-coil 2 | 2,2.10−2 | ns | 1,2 |
|
| Zinc finger protein 689 | 3,3.10−2 | ns | -1,17 |
|
| Oral cancer overexpressed 1 | 3,6.10−2 | ns | -1,23 |
|
| Endosulfine alpha | 3,6.10−2 | ns | 1,19 |
|
| Solute carrier family 39 (zinc transporter), member 10 | 3,4.10−2 | ns | 1,12 |
|
| Ankyrin repeat domain 37 | 4,5.10−3 | ns | 1,7 |
|
| Arginine/serine-rich protein 1 | 4,7.10−2 | ns | 1,14 |
|
| Chromosome 7 open reading frame 52 | 2,1.10−2 | ns | 1,14 |
|
| MAPKAPK5 antisense RNA 1 | 2,3.10−2 | ns | 1,27 |
|
| Chromosome 1 open reading frame 131 | 3,3.10−2 | ns | -1,29 |
|
| Interferon regulatory factor 2 binding protein 2 | 1,1.10−2 | ns | 1,15 |
|
| Bora aurora kinase A activator | 4,1.10−2 | ns | -1,24 |
|
| Hypoxia inducible lipid droplet-associated | 2,1.10−2 | ns | 1,38 |
|
| Frequently rearranged in advanced T-cell lymphomas 2 | 3,8.10−2 | ns | 1,15 |
|
| Adenosine A2b receptor | 4,1.10−2 | 1,2 | ns |
|
| WD repeat domain 37 | 2,1.10−2 | ns | -1,14 |
|
| Serine/arginine rich splicing factor 3 pseudogene | 2.10−2 | ns | -1,16 |
|
| Desmocollin 2 | 1,3.10−2 | 1,2 | ns |
|
| Ras homologue family member F (in Filopodia) | 1,3.10−2 | 1,23 | ns |
|
| Keratin 80 | 4,1.10−2 | 1,21 | ns |
|
| Transmembrane protein 139 | 4.10−2 | 1,19 | ns |
|
| Ral GEF with PH domain and SH3 binding motif 2 | 4,1.10−2 | 1,17 | ns |
|
| Similar to mitogen-activated protein kinase kinase 3 isoform A | 4,8.10−2 | 1,23 | ns |
Fold change (FC) are expressed in comparison with negative control (DMEM treatment), ns means that gene was not statistically significantly regulated by the treatment
Fig 5ErmineJ significant GO pathways modulated by L. rhamnosus CNCMI–4317 in IECs.
Fig 6In vivo, (a) FIAF circulating level, (b) Fiaf expression in the gut, and (c) IL7. (a-c) Circulating Fiaf and Il–7 was measured using Elisa tests. (b) Fiaf expression was determined via RT-qPCR.
Stars indicate p<0.05 (*) in comparison with GF control group (PBS). DSI (distal small intestine), PSI (proximal small intestine), P = 0.14 (Student’s t-test) corresponds to L. rhamnosus CNCMI– 4317 versus control (PBS).